乐德木单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 转化生长因子β2 |
| 临床资料 | |
| ATC码 |
|
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 285985-06-0  [NIH] |
| ChemSpider |
|
| UNII | |
乐德木单抗（INN：lerdelimumab；开发代号：CAT-152）是一种人单克隆抗体，也是一种针对转化生长因子β2的免疫抑制剂。[1][2]
该药物的开发是为了减少青光眼引流手术后的疤痕。[3]由于该病症的试验结果不成功，开发于2005年底停止。[4]
参考资料
[编辑]- ^ Cordeiro, M. Francesca. Technology evaluation: lerdelimumab, Cambridge Antibody Technology. Current Opinion in Molecular Therapeutics. 2003-04, 5 (2). ISSN 1464-8431. PMID 12772512.
- ^ Mead, Anna L.; Wong, Tina T. L.; Cordeiro, M. Francesca; Anderson, Ian K.; Khaw, Peng T. Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Investigative Ophthalmology & Visual Science. 2003-08, 44 (8) [2024-05-26]. ISSN 0146-0404. PMID 12882787. doi:10.1167/iovs.02-0978. （原始内容存档于2024-05-26）.
- ^ Lerdelimumab. Drugs in R&D. 1 February 2002, 3 (2): 106–8. PMID 12001808. doi:10.2165/00126839-200203020-00006.
- ^ CAT abandons Trabio after second clinical trial failure. The Pharma Letter. 28 March 2005.